Proposed Bill No. 5485 aims to establish a captive insurance company in Connecticut to facilitate the bulk purchase and distribution of glucagon-like peptide-1 receptor antagonist prescription drugs for individuals struggling with obesity. The bill includes an appropriation of ten million dollars from the General Fund for the fiscal year ending June 30, 2026, to support this initiative. The captive insurance company will focus on acquiring these prescription drugs from manufacturers and distributing them to qualifying individuals who meet a means-tested criteria and are unable to obtain the medications through their health insurers.

The bill proposes amendments to title 38a of the general statutes, specifically inserting provisions for the establishment of the captive insurance company and its funding. There are no deletions from current law mentioned in the text provided. The overall goal of the bill is to improve access to necessary obesity treatment medications for those in need within the state.